• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.

作者信息

Omachi Naoki, Shimizu Shigeki, Kawaguchi Tomoya, Tezuka Kenji, Kanazu Masaki, Tamiya Akihiro, Asami Kazuhiro, Okishio Kyoichi, Kitaichi Masanori, Atagi Shinji

机构信息

Departments of *Internal Medicine, †Laboratory Medicine and Pathology, and ‡Surgery, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan.

出版信息

J Thorac Oncol. 2014 Jun;9(6):e40-2. doi: 10.1097/JTO.0000000000000103.

DOI:10.1097/JTO.0000000000000103
PMID:24828670
Abstract
摘要

相似文献

1
A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.一例伴有EML4-ALK重排且对ALK抑制剂克唑替尼耐药的大细胞神经内分泌癌病例。
J Thorac Oncol. 2014 Jun;9(6):e40-2. doi: 10.1097/JTO.0000000000000103.
2
A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.一例对克唑替尼耐药的肺腺癌病例，携带一种新型EML4-ALK变异体，EML4的第6外显子与ALK的第18外显子融合。
J Thorac Oncol. 2016 Oct;11(10):e126-8. doi: 10.1016/j.jtho.2016.07.008.
3
Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.下一代测序在肺大细胞神经内分泌癌中鉴定出一种新型的对克唑替尼敏感的PLB1-ALK重排。
Clin Lung Cancer. 2021 May;22(3):e366-e370. doi: 10.1016/j.cllc.2020.05.026. Epub 2020 Jun 2.
4
Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.一名ALK阳性肺癌患者的循环肿瘤细胞扩增，呈现EML4-ALK重排并伴有耐药突变，可用于药物敏感性测试：一项病例研究。
J Thorac Oncol. 2017 Feb;12(2):397-402. doi: 10.1016/j.jtho.2016.07.027. Epub 2016 Aug 6.
5
Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel Fusion Oncokinase.ALK免疫组化在肺大细胞神经内分泌癌最佳治疗策略中的应用及一种新型融合癌激酶的鉴定
Anticancer Res. 2019 Jan;39(1):413-420. doi: 10.21873/anticanres.13127.
6
Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.伴有间变性淋巴瘤激酶（ALK）重排且对阿来替尼有反应的大细胞神经内分泌癌
Intern Med. 2018 Mar 1;57(5):713-716. doi: 10.2169/internalmedicine.9368-17. Epub 2017 Nov 20.
7
Crizotinib in the management of advanced-stage non-small-cell lung cancer.克唑替尼用于晚期非小细胞肺癌的治疗
Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314.
8
Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.三例棘皮动物微管相关蛋白样 4-间变性淋巴瘤激酶融合型癌基因阳性非小细胞肺癌患者对克唑替尼的良好反应。
Cancer Sci. 2011 Aug;102(8):1602-4. doi: 10.1111/j.1349-7006.2011.01970.x.
9
Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.克唑替尼对两例伴有EML4-ALK重排的肺腺癌脑转移无效。
J Thorac Oncol. 2013 Apr;8(4):e30-1. doi: 10.1097/JTO.0b013e318288dc2d.
10
[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].[具有转化型EML4-ALK融合基因的患者对克唑替尼耐药的机制]
Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):862-4. doi: 10.3760/cma.j.issn.0529-5807.2012.12.020.

引用本文的文献

1
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.肺大细胞神经内分泌癌的综合分子与临床特征
Nat Commun. 2025 Aug 19;16(1):7717. doi: 10.1038/s41467-025-63091-0.
2
Misdiagnosis of bilateral breast metastases as primary benign tumors secondary to lung large-cell neuroendocrine carcinoma: a case report.双侧乳腺转移瘤误诊为肺大细胞神经内分泌癌继发的原发性良性肿瘤：一例报告
Discov Oncol. 2025 Jun 14;16(1):1101. doi: 10.1007/s12672-025-02855-y.
3
[Research Progress on Molecular Subtypes and Precision Therapy 
of Pulmonary Large Cell Neuroendocrine Carcinoma].
[肺大细胞神经内分泌癌的分子亚型与精准治疗研究进展]
Zhongguo Fei Ai Za Zhi. 2025 Feb 20;28(2):146-154. doi: 10.3779/j.issn.1009-3419.2025.102.06.
4
Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma.大细胞神经内分泌癌的一种亚型——联合大细胞神经内分泌癌的临床特征及治疗管理
Front Oncol. 2024 Oct 22;14:1449490. doi: 10.3389/fonc.2024.1449490. eCollection 2024.
5
Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma.肺大细胞神经内分泌癌的基因特征及治疗策略进展
Front Med (Lausanne). 2024 Feb 27;11:1326426. doi: 10.3389/fmed.2024.1326426. eCollection 2024.
6
Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.两例病例报告：EML4-ALK重排的大细胞神经内分泌癌及文献综述
Front Oncol. 2023 Nov 1;13:1227980. doi: 10.3389/fonc.2023.1227980. eCollection 2023.
7
The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung.肺癌大细胞神经内分泌癌的未满足诊断和治疗需求。
Curr Oncol. 2023 Jul 27;30(8):7218-7228. doi: 10.3390/curroncol30080523.
8
EML4-ALK rearrangement of lung large cell neuroendocrine carcinoma: a case report.肺大细胞神经内分泌癌的EML4-ALK重排：一例报告
Ann Transl Med. 2023 Jan 31;11(2):134. doi: 10.21037/atm-22-6062. Epub 2023 Jan 11.
9
Pulmonary Combined Large Cell Neuroendocrine Carcinoma.肺混合型大细胞神经内分泌癌。
Pathol Oncol Res. 2022 Nov 23;28:1610747. doi: 10.3389/pore.2022.1610747. eCollection 2022.
10
Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.洛拉替尼与 ALK+大细胞神经内分泌肺癌的复合突变：一例报告。
Cold Spring Harb Mol Case Stud. 2022 Oct 28;8(6). doi: 10.1101/mcs.a006234. Print 2022 Oct.